NovaDel's NitroMist Is "Approvable" At FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
The company expects full approval for the 505(b)(2) product following completion of manufacturing validation commitments. Par will co-promote the product, which administers nitroglycerine to the oral mucosa.
You may also be interested in...
Novadel’s NitroMist Application Moves Forward With Complete Response
The nitroglycerin NDA has an updated user fee date in early November.
India Highlights "Public Interest" To Reign In Prices For Non-Scheduled Drugs
Dr. Reddy's, GSK, Ranbaxy and UCB among manufacturers that could see prices reduced under government order that reflects issues raised in Gleevec patent dispute.